The global iron deficiency injectables market grew at a CAGR of around 8% during 2014-2019. Iron deficiency injectables refer to drugs prescribed to treat iron deficiency and delivered by intravenous (IV) infusion in the body. These IV drugs offer several benefits over oral medications by ensuring faster absorption of the infused supplements. Iron deficiency injectables also help in overcoming poor adherence, non-compliance, and adverse gastrointestinal effects of oral medicines.
The market for iron deficiency injectables is currently being catalysed by the rising geriatric population and increasing prevalence of chronic conditions such as cancers, chronic kidney disease and rising number of patients undergoing dialysis. Furthermore, rising healthcare expenditures, improving diagnosis rates and strong growth from emerging markets is also expected to create a positive impact on market growth. The high prevalence of iron deficiency anemia due to the polycystic ovary syndrome (PCOS) and the rising incidences of hemodilution in pregnant women are also bolstering the demand for iron-deficiency injectables. Furthermore, the market is also being driven by the growing health concerns towards the intestinal degradation by oral iron therapies. Apart from this, the emergence of dextran-free intravenous formulations for treating iron deficiency is also augmenting the market growth. Looking forward, we expect the global iron deficiency injectables market to continue its strong growth during 2020-2025.
Breakup by Product Type:
Breakup by Indication:
Breakup by Branded/Generics:
Breakup by Distribution Channel:
Breakup by Region:
The report has also analysed the competitive landscape of the market along with the profiles of the key players.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at